Articles

Multiple myeloma: Practical recommendations for the management of early relapses 2024

BJH - volume 15, issue 4, june 2024

M.C. Vekemans MD, N. Kint MD, PhD, G. Claes MD, C. Doyen MD, V. Galle MD, C. Jacquy MD, PhD, H. Maes MD, N. Meuleman MD, PhD, O. Rizzo MD, A. Salembier MD, H. Schots MD, PhD, G. Verstraete MD, M. Delforge MD, PhD

SUMMARY

Despite the increasing availability of more effective treatments for newly diagnosed multiple myeloma (NDMM) patients that provide longer disease-free periods, almost all patients will experience a relapse. Managing relapse after regimens that have included a proteasome inhibitor (PI), an immunomodulatory drug (IMID), and often an anti-CD38 monoclonal antibody can be challenging, but therapeutic options have greatly increased over the past decades. This review covers the current second-line therapeutic options and provides updated information on novel agents for the treatment of early relapses in MM patients.

(BELG J HEMATOL 2024;15(4):158–64)

Read more

Multiple myeloma: Practical recommendations for front-line therapy 2024

BJH - volume 15, issue 3, may 2024

M.C. Vekemans MD, N. Meuleman MD, PhD, N. Kint MD, PhD, G. Claes MD, C. Doyen MD, V. Galle MD, C. Jacquy MD, PhD, H. Maes MD, O. Rizzo MD, A. Salembier MD, H. Schots MD, PhD, G. Verstraete MD, M. Delforge MD, PhD

SUMMARY

With the introduction of immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal antibodies, major improvements have been achieved in the treatment and outcome of multiple myeloma. Different treatment combinations are now in use and quadruplets have been investigated with success. This rapidly changing therapeutic landscape urges for an update on practical guidelines. Based on an extensive review of the recent literature, we propose recommendations on myeloma management, to be used by haematologists as a reference for daily practice.

(BELG J HEMATOL 2024;15(3):103–16)

Read more

O5 Inhibition of multiple myeloma exosomes prevents bone loss and reduces tumor growth.

BJH - 2018, issue Abstract Book BHS, february 2018

S. Faict , K. De Veirman , dr. K. Maes , E. De Bruyne , H. Schots MD, PhD, R. Heusschen PhD, J. Caers MD, PhD, K. Vanderkerken PhD, E. Menu

Read more

P26 Immunomagnetic enrichment of circulating tumor cells prior to tumor Ig specific qASO-PCR enhances the sensitivity of minimal residual disease detection in multiple myeloma

BJH - 2018, issue Abstract Book BHS, february 2018

W. De Brouwer MD, J. Van Der Straeten MSc, C. Demanet MD, PhD, H. Schots MD, PhD, M. Bakkus PhD, I. Van Riet PhD

Read more

P59 Benchmarking of the quality of the transfusion policy in Belgian hospitals between 2012–2016 – a collaborative and iterative method

BJH - 2018, issue Abstract Book BHS, february 2018

J. Vanden Broeck , K. Beeckman , C. Gérard , M. Haelterman , V. Deneys , H. Schots MD, PhD

Read more